Trademark: 97298515
Word
GC BIOPHARMA
Status
Pending
Status Code
731
Status Date
Wednesday, January 17, 2024
Serial Number
97298515
Mark Type
3000
Filing Date
Monday, March 7, 2022
Published for Opposition
Tuesday, December 13, 2022

Trademark Owner History
Green Cross Holdings Corporation - Owner At Publication

Classifications
5 Medicines for humans used for the prevention and treatment of cancer, cerebrovascular thrombosis, myocardial infarctions, peripheral artery occlusions, pulmonary embolisms, thrombocytopenia, thrombophlebitis, Japanese Encephalitis, Hepatitis B Virus, Hepatitis C Virus, Immunodeficiency disease, Human Immunodeficiency Virus, rare disease, Hunter Syndrome, Hemophilia, Hemophilia A, arthritis, osteoarthritis, arthritis deformans, periarthritis humeroscapularis, tendinitis, peritendinitis, humeral epicondylitis, idiopathic thrombocytopenic purpura, Guillain-barre syndrome, Kawasaki syndrome, Clostridium tetani, virus infection, influenza, bacterial infection and chronic pain; Medicines for humans, namely, blood plasma-derivatives, namely, albumins, immunoglobulins, and blood clotting factors; Medicated plasters; Vaccines; Biological preparations for medical or veterinary purposes, namely, biological preparations used for the prevention and treatment of cancer, cerebrovascular thrombosis, myocardial infarctions, peripheral artery occlusions, pulmonary embolisms, thrombocytopenia, thrombophlebitis, Japanese Encephalitis, Hepatitis B Virus, Hepatitis C Virus, Immunodeficiency disease, Human Immunodeficiency Virus, rare disease, Hunter Syndrome, Hemophilia, Hemophilia A, arthritis, osteoarthritis, arthritis deformans, periarthritis humeroscapularis, tendinitis, peritendinitis, humeral epicondylitis, idiopathic thrombocytopenic purpura, Guillain-barre syndrome, Kawasaki syndrome, Clostridium tetani, virus infection, influenza, bacterial infection and chronic pain; Biological preparations for medical or veterinary purposes, namely, blood plasma-derivatives, namely, albumins, immunoglobulins, and blood clotting factors; Dietary and nutritional supplements
35 Wholesale distributorships and retail store services featuring pharmaceutical products; Export and import agencies in the field of pharmaceutical products; Wholesale store services featuring biological preparations for medical purposes; Retail store services featuring biological preparations for medical purposes; Retail store services featuring pharmaceutical preparations for the treatment of cells; Retail store services featuring medical instruments; Retail store services featuring medical apparatus; Retail store services featuring medical genetic analyzer; Retail store services featuring electromedical diagnostic instruments; Wholesale store services featuring pharmaceutical preparations for the treatment of cells; Wholesale store services featuring medical instruments; Wholesale store services featuring medical apparatus; Wholesale store services featuring medical genetic analyzer; Wholesale store services featuring electromedical diagnostic instruments; all the foregoing excluding services in the field of industrial, institutional, commercial and janitorial equipment and supplies; Financial intermediary services, namely, facilitating the channeling of funds between lenders and borrowers by connecting those with a financial surplus with those having a financial deficit in the field of pharmaceutical products and medical equipment; Operation of a business for others, namely, wholesale distributorships and retail stores featuring pharmaceutical products; Procurement, namely, purchasing pharmaceutical products for other businesses
42 Research and development of vaccines and medicines; Research and development, laboratory and scientific research in the field of pharmaceuticals, blood plasma preparations, recombinant proteins and antibodies; Conducting clinical studies of medicines for medical research purposes; Clinical research in the nature of performing biopsies for medical research; Product research and development of medical products; Conducting technical project studies, namely, engineering services in the nature of technical project planning and design engineering of medical products; Testing, inspection or research of pharmaceuticals; Scientific research relating to biology; Scientific research in the field of genetic engineering; Research and development of technology for biotechnology; Scientific research in the fields of biomedicine; Laboratory research in the field of biology; Product development of cell therapy products; Drug discovery services; Research and development in the pharmaceutical and biotechnology fields; Scientific research in the field of gene analysis; Medical studies, namely, medical laboratory services; Research and development of technology for medicinal chemical manufacturing; Medical research services relating to clinical data
The mark consists of a stylized rounded cross with the top and right arms in red fading toward the middle to orange then to yellow, and the left and lower arms in green; to the right of the cross are the stylized wording "GC Biopharma" in dark blue; the color white is not claimed as a feature of the mark and represents background and transparent areas only.
The color(s) green, yellow, orange, red, and dark blue is/are claimed as a feature of the mark.
"BIOPHARMA"

Trademark Events
Jan 19, 2024
Notice Of Approval Of Extension Request E-Mailed
Jan 17, 2024
Sou Extension 2 Granted
Jan 17, 2024
Sou Extension 2 Filed
Jan 17, 2024
Sou Teas Extension Received
Mar 18, 2023
Notice Of Approval Of Extension Request E-Mailed
Mar 16, 2023
Sou Extension 1 Granted
Mar 16, 2023
Sou Extension 1 Filed
Mar 16, 2023
Sou Teas Extension Received
Feb 7, 2023
Noa E-Mailed - Sou Required From Applicant
Dec 13, 2022
Official Gazette Publication Confirmation E-Mailed
Dec 13, 2022
Published For Opposition
Nov 23, 2022
Notification Of Notice Of Publication E-Mailed
Nov 4, 2022
Approved For Pub - Principal Register
Nov 4, 2022
Examiner's Amendment Entered
Nov 4, 2022
Notification Of Examiners Amendment E-Mailed
Nov 4, 2022
Examiners Amendment E-Mailed
Nov 4, 2022
Examiners Amendment -Written
Oct 28, 2022
Assigned To Examiner
Mar 12, 2022
Notice Of Design Search Code E-Mailed
Mar 11, 2022
New Application Office Supplied Data Entered
Mar 10, 2022
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24